not-yet-known not-yet-known not-yet-known unknown References: 1.Korubo KI, Okoye HC, Efobi CC. The economic burden of malignant and premalignant hematological diseases in Southern Nigeria. Niger J Clin Pract. 2018 Nov;21(11):1396-1402. 2. Papon N, Bougnoux ME, d’Enfert C. Tracing the Origin of Invasive Fungal Infections. Trends Microbiol. 2020 Apr;28(4):240-242. 3. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009 Feb 1;48(3):265-73. 4. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):99-109. 5. Daly P, Kavanagh K. Pulmonary aspergillosis: clinical presentation, diagnosis and therapy. Br J Biomed Sci. 2001;58(3):197-205. 6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002 Apr 1;34(7):909-17. Doi: 10.1086/339202. Epub 2002 Feb 26. 7. Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia. 2009 Dec;168(6):299-311. 8. Loubet D, Sarton B, Lelièvre L, Grouteau G, Iriart X, Chauvin P, Fillaux J, Valentin A, Berry A, Silva S, Bonneville F, Cassaing S, Guemas E. Fatal mucormycosis and aspergillosis coinfection associated with haemophagocytic lymphohistiocytosis: A case report and literature review. J Mycol Med. 2023 Mar;33(1):101325. doi: 10.1016/j.mycmed.2022.101325. Epub 2022 Aug 8. 9. Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014 Sep-Oct;80(5):384-92. 10. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019 Jan;25(1):26-34. 11. Suleman A, Padmore R, Faught C, Cowan J. Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL). IDCases. 2019 May 31;17:e00566. 12. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007 Dec;20(12):993-1015. 13. Park SY, Kim SH, Choi SH, Sung H, Kim MN, Woo JH, Kim YS, Park SK, Lee JH, Lee KH, Lee SG, Han DJ, Lee SO. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis. 2010 Aug 1;12(4):309-15. 14. Myoken Y, Sugata T, Mikami Y, Murayama SY, Fujita Y. Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. J Oral Maxillofac Surg. 2008 Sep;66(9):1905-12. 15. Tugsel Z, Sezer B, Akalin T. Facial swelling and palatal ulceration in a diabetic patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):630-6. 16. Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L. Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016 Nov 15;63(10):1340-1348. 17. White PL, Posso RB, Barnes RA. Analytical and Clinical Evaluation of the PathoNostics AsperGenius Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs Directly from Plasma Samples. J Clin Microbiol. 2017 Aug;55(8):2356-2366. 18. Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015 Dec 30;2015(12):CD007394. 19. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. 20. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017 Mar;102(3):433-444. 21. Koehler P, Denis B, Denning D W, Gangneux J P, Hoenigl M , Kontoyianni D P, et al. “European Confederation of Medical Mycology Expert Consult—an ECMM Excellence Center Initiative.” Mycoses, vol. 63, no. 6, 13 Apr. 2020, pp. 566–572, 22. Bergantim R, Rios E, Trigo F, Guimarães JE. Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia. Clin Drug Investig. 2013 Feb;33 Suppl 1:S51-5. 23. Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015 Nov 23;2015(11):CD010481. 24. Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, Herbrecht R, Wolff M, Ribaud P, Lortholary O; French Mycosis Study Group. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015 Nov;70(11):3116-23. 25. Miller MA, Molina KC, Gutman JA, Scherger S, Lum JM, Mossad SB, et al. Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents. Open Forum Infect Dis. 2020 Dec 30;8(2):ofaa646.